MF
Therapeutic Areas
atai Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BPL-003 | Treatment-Resistant Depression | Phase 2 |
| VLS-01 | Treatment-Resistant Depression | Phase 2 |
| EMP-01 | Social Anxiety Disorder | Phase 2 |
| Discovery Programs (Novel 5-HT2A agonists) | Opioid Use Disorder and Treatment-Resistant Depression | Preclinical |
Leadership Team at atai Life Sciences
SR
Srinivas Rao
Co-Founder and Chief Executive Officer
CA
Christian Angermayer
Founder and Chairman of the Board
GK
Gerd Kochendoerfer
Chief Operating Officer
KC
Kevin Craig
Chief Medical Officer
AJ
Anne Johnson
Chief Accounting Officer
RC
Robert Conley
Chief Research and Development Officer
GS
Glenn Short
Chief Scientific Officer
RB
Ryan Barrett
Chief Legal and Business Officer
SB
Scott Braunstein
Vice-Chairman of the Board and Director
LF
Laurent Fischer
Director